Codon Devices Receives $20,000,000 Series B Financing Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fc4162b4-2b59-4c50-9bca-e3c465c78729&Preview=1
Date 12/19/2006
Company Name Codon Devices
Mailing Address One Kendall Square, Building 300, 3rd Floor Cambridge, MA 02139
Company Description Codon Devices is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices’ proprietary synthesis and design technologies improve the productivity, throughput and flexibility of its industrial, pharmaceutical and academic customers in a paradigm shift to what the company calls Constructive Biology™. The company’s focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and Bio-energy. Codon Devices’ BioFAB™ platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology.
Proceeds Purposes John P. Danner, President and CEO of Codon Devices said, “We will utilize this significant capital infusion to further industrialize our proprietary BioFAB™ production platform, aggressively expand our novel protein and metabolic engineering capabilities, and rapidly globalize our sales and marketing presence.”